首页> 美国卫生研究院文献>Springer Open Choice >Role of Endocrine Gland-Derived Vascular Endothelial Growth Factor (EG-VEGF) and Its Receptors in Adrenocortical Tumors
【2h】

Role of Endocrine Gland-Derived Vascular Endothelial Growth Factor (EG-VEGF) and Its Receptors in Adrenocortical Tumors

机译:内分泌腺源性血管内皮生长因子(EG-VEGF)及其受体在肾上腺皮质肿瘤中的作用。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Angiogenesis is essential for tumor growth and metastasis. Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) is an angiogenic factor predominantly expressed in steroidogenic organs like the adrenal gland, ovary, testes, and placenta. EG-VEGF has antiapoptotic, mitogenic, and chemoattractive properties mediated via the two G protein-coupled receptors prokineticin receptor 1 (PKR1) and prokineticin receptor 2 (PKR2). We investigated the expression of EG-VEGF and its receptors in a large number of normal adrenal glands (NAG), adrenocortical adenomas (ACA), and carcinomas (ACC) using real-time PCR (NAG, n = 12; ACA, n = 24; and ACC, n = 30) and immunohistochemistry (NAG, n = 9; ACA, n = 23; and ACC, n = 163) and evaluated its impact on patients’ survival. EG-VEGF, PKR1, and PKR2 mRNA and protein are expressed in NAG and the vast majority of ACA and ACC samples. The mean EG-VEGF mRNA expression was significantly lower in ACC (606.5 ± 77.1 copies) compared to NAG (4,043 ± 1,111) and cortisol-producing adenomas (CPA) (4,433 ± 2,378) (p < 0.01 and p < 0.05, respectively). However, cytoplasmic and nuclear EG-VEGF protein expression was either significantly higher or similar in ACC (H score 2.4 ± 0.05, p < 0.05 and 1.7 ± 0.08, n.s., respectively) compared to NAG (1.8 ± 0.14 and 1.7 ± 0.2). Nuclear protein expression of either EG-VEGF or PKR1 or both is predictive for a higher mortality compared to patients without nuclear expression (hazard ratio (HR) = 5.15; 95 % confidence interval (CI) = 1.24–21.36, n = 100, p = 0.02 independent of age, sex, and tumor stage). These findings suggest that EG-VEGF and its receptor PKR1 might play a role in the pathogenesis of adrenocortical tumors and could serve as prognostic markers for this rare malignant disease.Electronic supplementary materialThe online version of this article (doi:10.1007/s12672-015-0236-z) contains supplementary material, which is available to authorized users.
机译:血管生成对于肿瘤的生长和转移至关重要。内分泌腺衍生的血管内皮生长因子(EG-VEGF)是主要在类固醇生成器官如肾上腺,卵巢,睾丸和胎盘中表达的血管生成因子。 EG-VEGF具有抗凋亡,促有丝分裂和趋化特性,这是通过两个G蛋白偶联受体促动素受体1(PKR1)和促动素受体2(PKR2)介导的。我们使用实时荧光定量PCR(NAG,n = 12,ACA,n ==)研究了EG-VEGF及其受体在大量正常肾上腺(NAG),肾上腺腺瘤(ACA)和癌(ACC)中的表达。 24; ACC,n = 30; NAC,n = 9; ACA,n = 23; ACC,n = 163;并评估其对患者生存的影响。 EG-VEGF,PKR1和PKR2 mRNA和蛋白质在NAG和绝大多数ACA和ACC样品中表达。与NAG(4,043±1,111)和产生皮质醇的腺瘤(CPA)(4,433±2,378)相比,ACC(606.5±77.1拷贝)中平均EG-VEGF mRNA表达显着降低(分别为p <0.01和p <0.05) 。然而,与NAG(1.8±0.14和1.7±0.2)相比,ACC中的细胞质和核EG-VEGF蛋白表达显着较高或相似(H评分分别为2.4±±0.05,p <0.05和1.7±0.08,n.s。)。与无核表达的患者相比,EG-VEGF或PKR1或两者的核蛋白表达可预测更高的死亡率(危险比(HR)= 5.15; 95%置信区间(CI)= 1.24–21.36,n = 100,p = 0.02,与年龄,性别和肿瘤分期无关。这些发现表明EG-VEGF及其受体PKR1可能在肾上腺皮质肿瘤的发病机制中起作用,并且可以作为这种罕见恶性疾病的预后标志物。电子补充材料本文的在线版本(doi:10.1007 / s12672-015- 0236-z)包含补充材料,授权用户可以使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号